SEC Filing Analysis: CHAMPIONS ONCOLOGY, INC. (CSBR)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: A director was granted stock options for 21,216 shares, representing a potential 0.15% dilution to shareholders if exercised.
• Market Impact: Neutral. This is a routine compensation grant, not an open-market transaction, but it does increase insider alignment with shareholders.

Company Information

Field	Value
Company	CHAMPIONS ONCOLOGY, INC.
Ticker Symbol	CSBR
CIK	0000771856
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	ACKERMAN JOEL
CIK	0001220630
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-05
Transaction Code	A (Award)
Security Type	Option to purchase Common Stock
Shares Involved	21,216
Price Per Share	$6.80 (Exercise Price)
Total Value	$144,268.80 (Notional)
Shares Owned After	21,216 (options)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$144,268.80 (Notional)
% of Market Cap	0.16%
Shares Transacted	21,216
% of Shares Outstanding	0.15%
Post-Transaction Ownership	21,216 options (potential 0.15% of outstanding)
Materiality Assessment	Moderate

Impact Evaluation

• Market Cap Context: For a nano-cap company with a $90 million market cap, this grant is a moderately sized compensation award.
• Ownership Concentration: This grant establishes a new derivative position for the director, aligning their incentives with shareholders.
• Dilution Impact: The potential dilution from this grant is minor at 0.15% of total shares outstanding, which is not expected to materially affect existing shareholders.
• Transaction Significance: The grant is of medium significance. While it's a routine form of compensation, the size relative to the company's outstanding shares (0.15%) makes it a notable award that meaningfully aligns the director's interests with shareholder value creation.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a non-market transaction representing director compensation. It does not signal new information about the company's immediate prospects but is a standard governance practice to incentivize leadership.

Volume & Sentiment

• Expected Volume Impact: Negligible. As this is not an open-market trade, it will not directly impact trading volume.
• Sentiment Indicator: Neutral. The market generally views such grants as a standard cost of business for public companies.

Investment Insights

Positive Market Indicators

• Aligns a director's long-term interests with those of common stockholders.

Risk Factors

• Represents a minor potential for shareholder dilution if and when the options are exercised.

Key Takeaways

1. Director Joel Ackerman was granted 21,216 stock options as part of his compensation.
2. The grant has a notional value of approximately $144k and represents a potential 0.15% of shares outstanding.
3. This is a standard compensation practice and is considered neutral from a market signaling perspective.

Additional Context

Transaction Notes

• Vesting Schedule: The options vest in four equal installments over a twelve-month period, beginning November 5, 2025.